Track topics on Twitter Track topics that are important to you
SHREWSBURY, N.J., June 5, 2015 (GLOBE NEWSWIRE) -- InterCloud Systems, Inc. (Nasdaq:ICLD), a leading provider of cloud networking orchestration and automation solutions and services announced today that it was recently awarded contracts by new clients valued at over $1.5 million to provide engineering, design and planning services for the deployment of new state of the art communications systems. Comprehensive services include but are not limited to: investigatory & due diligence activities, regulatory filings & compliance activities, civil/structural design, analysis and permitting services. Further details are withheld due to the nature of the project and associated critical infrastructure.
Mark Munro, CEO of InterCloud Systems stated; "InterCloud continues to win new business from existing clients and more importantly from new clients with large scale next-generation network opportunities. This new customer relationship is a great example of our organization's ability to move quickly to meet the demands of customers with large scale, complex wireless networks. This opportunity has only been in our sales pipeline since March of 2015 and is expected to be completed over the next several months. This new business confirms that InterCloud's distinctive and proven suite of services have a competitive advantage within the enterprise and service provider markets and demonstrates our ability to provide single source and complex deployment services to our clients across large geographic territories. InterCloud is positioned well to take advantage of this and other next-generation network growth opportunities throughout 2015 and beyond."
About InterCloud Systems, Inc.
InterCloud Systems, Inc. is a single-source provider of end-to-end information technology (IT) and next-generation network solutions including Software Defined Networking (SDN) and Network Function Virtualization (NFV) to the telecommunications service provider (carrier) and corporate enterprise markets through cloud solutions and professional services. Additional information regarding InterCloud may be found on InterCloud's website at www.intercloudsys.com.
The above news release contains forward-looking statements. The statements contained in this document that are not statements of historical fact, including but not limited to, statements identified by the use of terms such as "anticipate," "appear," "believe," "could," "estimate," "expect," "hope," "indicate," "intend," "likely," "may," "might," "plan," "potential," "project," "seek," "should," "will," "would," and other variations or negative expressions of these terms, including statements related to expected market trends and the Company's performance, are all "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performances, and are subject to a wide range of external factors, uncertainties, business risks, and other risks identified in filings made by the company with the Securities and Exchange Commission. Actual results may differ materially from those indicated by such forward-looking statements. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based except as required by applicable law and regulations.
CONTACT: Investor Relations InterCloud Systems, Inc. Telephone 561-988-1988 Website www.intercloudsys.comNEXT ARTICLE
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...